Xinepa® is a nutraceutical product already in possession of a double patent in Italy, of technology and formula, which has been recognized for the innovation and uniqueness of the composition intended for the treatment of neuropathies and neuropathic pain by one of the most advanced countries in the world in the #nutraceutical market.

It is the result of research carried out by Kolinpharma which has demonstrated its mechanism of action and validity through in vitro and clinical studies, the results of which have been published in International Technical-Scientific Journals.

Rita Paola Petrelli, President of Kolinpharma®, comments: "Our strategy of competitive positioning in key countries outside of Italy continues, through the certification of the most innovative products in our portfolio.

Israel is a pioneering country, with high levels of control and restrictions also due to Kosher regulations, the new patent represents for us a source of pride and a confirmation of the quality of our R&D activity with increasingly innovative and effective products. "